MedAxiom has been acquired by American College of Cardiology
The private shareholders of MedAxiom have sold the company to American College of Cardiology, Inc.
MedAxiom was founded in 2001 and is the nation’s leading cardiovascular performance community serving physician practices by providing expert consulting, networking and membership services including data analytics, program excellence tools and educational events to improve business and patient care outcomes.
American College of Cardiology is a trade association that caters to cardiovascular professionals to learn, grow and share knowledge about cardiovascular care and heart health. It also reviews and offers certification courses focusing on cardiovascular diseases. The association helps in the formation of cardiology guidelines, clinical data standards and health policies. Additionally, it publishes cardiovascular journals which focus on cardiovascular diseases, including original clinical studies, translational investigations with clear clinical relevance, state-of-the-art papers, review articles, and editorials interpreting and commenting on the research presented. American College of Cardiology was founded in 1949 and is based in Washington, DC.
Oaklins’ teams in Jacksonville and Savannah acted as financial advisors to MedAxiom in this transaction.
Jennifer Linville
Founding CEO, MedAxiom
Talk to the deal team
Related deals
Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.
Learn moreAfric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Learn moreXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn more